Unfortunately, the expression of PD-L1 has not yet shown to be correlated to treatment response to PD-L1/PD-1 inhibitors in NKTCL; subsequent papers have also suggested that EBV latency factors such as LMP1 could induce the expression of PD-L1 in NKTCL (179), and that induced PD-L1 could be a factor of resistance to immune checkpoint blockade instead, thus explaining an apparent lack of correlation between PD-L1 expression and response to PD-1/PD-L1 inhibitors (180). The gene discussed is PDCD1; the disease is extranodal nasal NK/T cell lymphoma.